CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-06 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −4,875 | $22.72 | $111K | 0 |
| 2024-05-06 | Patel Anish CHIEF OPERATING OFFICER | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −4,875 | 55,842 | ||
| 2024-05-03 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +1,000 | $2.48 | $2K | 1,000 |
| 2024-05-03 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,000 | $22.50 | $23K | 0 |
| 2024-05-03 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −1,000 | 221,120 | ||
| 2024-04-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2024-04-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −10,987 | $17.86 | $196K | 1,013 |
| 2024-04-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −1,013 | $18.48 | $19K | 0 |
| 2024-04-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 218,550 | ||
| 2024-04-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 3,250 |
| 2024-04-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,250 | $16.97 | $55K | 0 |
| 2024-04-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 222,120 | ||
| 2024-04-25 | Kintz Samuel PRESIDENT AND CEO | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2024-04-25 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −12,000 | $16.89 | $203K | 0 |
| 2024-04-25 | Kintz Samuel PRESIDENT AND CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 200,841 | ||
| 2024-04-15 | Heyman Richard A. Director | Sale 10b5-1 | −1,190 | $19.94 | $24K | 137,235 |
| 2024-04-15 | Heyman Richard A. Director | Sale 10b5-1 | −80 | $20.68 | $2K | 137,155 |
| 2024-04-11 | Patel Anish CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +14,903 | $2.48 | $37K | 17,500 |
| 2024-04-11 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −17,500 | $25.03 | $438K | 0 |
| 2024-04-11 | Patel Anish CHIEF OPERATING OFFICER | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −14,903 | 60,717 |
Page 21 of 37 · 724 trades